https://www.selleckchem.com/pr....oducts/crenolanib-cp
Maximally tolerated dose was not reached; however, the recommended phase II dose was 60 mg selinexor weekly after evaluating tolerability and discontinuation rates for each dose cohort. Analysis of patient blood samples revealed downregulation of XPO1 and several prosurvival markers. SINE compounds enhance the activity of CHO and . Selinexor in combination with R-CHOP was generally well tolerated and showed encouraging efficacy in NHL (NCT03147885). SINE compounds enhance the activity of CHO in vitro and in vivo. Selinexor
Like
Comment
Share
